{
    "nctId": "NCT00079118",
    "briefTitle": "Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer",
    "officialTitle": "Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 70,
    "primaryOutcomeMeasure": "Confirmed tumor response as measured by RECIST criteria",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed adenocarcinoma of the breast\n\n  * Metastatic disease\n* Previously treated with chemotherapy in the adjuvant setting and/or for metastatic disease\n* At least one unidimensionally measurable lesion\n\n  * At least 20 mm by CT scan or MRI OR at least 10 mm by spiral CT scan\n  * Superficial clinical lesions (e.g., skin nodules or palpable lymph nodes) are allowed\n  * Lesions on chest x-ray are allowed provided they are clearly defined and surrounded by aerated lung\n  * The following are not considered measurable:\n\n    * Bone lesions\n    * Ascites\n    * Leptomeningeal disease\n    * Pleural/pericardial effusion\n    * Inflammatory breast disease\n    * Lymphangitis cutis/pulmonis\n    * Cystic lesions\n* No known CNS metastases unless controlled by prior surgery and/or radiotherapy\n* Hormone receptor status:\n\n  * Estrogen receptor (ER) and/or progesterone receptor (PR) status known\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Male or female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* ECOG 0-2\n\nLife expectancy\n\n* At least 3 months\n\nHematopoietic\n\n* Granulocyte count \u2265 1,500/mm\\^3\n* Hemoglobin \u2265 8.0 g/dL\n* Platelet count \u2265 100,000/mm\\^3\n\nHepatic\n\n* Bilirubin \u2264 upper limit of normal (ULN)\n* Meets 1 of the following criteria:\n\n  * AST or ALT \u2264 ULN AND alkaline phosphatase \u2264 5 times ULN\n  * Alkaline phosphatase \u2264 ULN AND AST or ALT \u2264 5 times ULN\n  * AST or ALT \u2264 1.5 times ULN AND alkaline phosphatase \u2264 2.5 times ULN\n\nRenal\n\n* Creatinine \u2264 1.5 times ULN\n\nCardiovascular\n\n* No myocardial infarction within the past 180 days\n* No congestive heart failure\n* No unstable angina\n* No clinically significant pericardial effusion or arrhythmias\n\nOther\n\n* No active, unresolved infection\n* No prior severe hypersensitivity reaction to docetaxel, irinotecan, or any drug formulated with polysorbate 80\n* No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n* No grade 1 or greater sensory or motor neuropathy\n* No other concurrent severe condition that would preclude study participation\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Prior trastuzumab (Herceptin\u00ae) required for HER-2-positive patients (unless contraindicated)\n\nChemotherapy\n\n* See Disease Characteristics\n* More than 14 days since prior chemotherapy\n* No more than 2 prior chemotherapy regimens for metastatic disease\n* No prior irinotecan or docetaxel for metastatic disease\n\n  * Docetaxel as adjuvant therapy allowed\n* No other concurrent chemotherapy\n\nEndocrine therapy\n\n* Prior hormonal therapy required for patients with ER- and/or PR-positive tumors (unless contraindicated)\n\nRadiotherapy\n\n* See Disease Characteristics\n* At least 30 days since prior radiotherapy\n* No concurrent radiotherapy\n\nSurgery\n\n* See Disease Characteristics\n* At least 3 weeks since prior major surgery and recovered\n\nOther\n\n* More than 7 days since prior parenteral antibiotic therapy\n* No other concurrent experimental drugs",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}